ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Milo C. Engoren
Anoar Zacharias
Thomas A. Schwann
Christopher J. Riordan
Samuel J. Durham
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Engoren, M. C.
Right arrow Articles by Durham, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Engoren, M. C.
Right arrow Articles by Durham, S. J.
Related Collections
Right arrow Cardiac - pharmacology

Ann Thorac Surg 2002;74:1180-1186
© 2002 The Society of Thoracic Surgeons


Original article: cardiovascular

Effect of blood transfusion on long-term survival after cardiac operation

Milo C. Engoren, MD*a,c, Robert H. Habib, PhDb,c,d, Anoar Zacharias, MDb,c, Thomas A. Schwann, MDb,c, Christopher J. Riordan, MDb,c, Samuel J. Durham, MDb,c,d

a Department of Anesthesiology, Toledo, Ohio, USA
b Department ofCardiovascular Surgery, Toledo, Ohio, USA
c St. Vincent Mercy Medical Center, Toledo, Ohio, USA
d Medical College of Ohio, Toledo, Ohio, USA

Accepted for publication May 7, 2002.

* Address reprint requests to Dr Engoren, Department of Anesthesiology, St. Vincent Mercy Medical Center, 2213 Cherry St, Toledo, OH, USA 43608
e-mail: engoren{at}pol.net


    Abstract
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 Acknowledgments
 References
 
Background. Blood transfusions have been linked to increased morbidity and mortality. Bleeding during and after cardiac operations and the hemodilution effects of cardiopulmonary bypass commonly result in blood transfusions. Because we could not find any studies evaluating the effects of transfusion on long-term survival after cardiac operation, we sought to determine these effects.

Methods. We studied 1,915 patients who underwent first-time isolated coronary artery bypass operations between July 6, 1994 and December 31, 1997 at our institution. Patients with transfusions were compared with those who had not been transfused. Long-term survival data were obtained from the United States Social Security Death Index. Groups were compared by Cox proportional hazard models, Kaplan-Meier survival plots, and hazard functions.

Results. Six hundred forty-nine of 1,915 study patients (34%) received a transfusion during their hospitalization. Transfused patients were older, smaller, and more likely to be female, and had more comorbidity. Transfused patients also had twice the 5-year mortality (15% vs 7%) of nontransfused patients. After correction for comorbidities and other factors, transfusion was still associated with a 70% increase in mortality (risk ratio = 1.7; 95% confidence interval = 1.4 to 2.0; p = 0.001). By multivariate analysis, transfusion, peripheral vascular disease, chronic obstructive pulmonary disease, New York Heart Association functional class IV, and age were significant predictors of long-term mortality.

Conclusions. We found that blood transfusions during or after coronary artery bypass operations were associated with increased long-term mortality.


    Introduction
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 Acknowledgments
 References
 
Despite institutional efforts to curtail the frequency of blood transfusions in cardiac operations, the frequency remains high. Annually in the United States, more than 3 million patients receive more than 11 million units of transfused blood [1]. The decision to transfuse patients is invariably done to promote hemostasis or improve the carrying capacity of oxygen in the blood. However, there is little consensus on who should be transfused. Deciding when a patient requires transfusion of blood products varies significantly among surgeons and intensivists, even those at the same institution [2]. Moreover, a recent study suggests that up to two thirds of completed transfusions may be clinically inappropriate [3]. If transfusions were completely safe, differing thresholds would not matter. However, adverse reactions are associated with transfusion. Although febrile reactions appear to be benign, hemolytic [4] and infectious complications [5] may occur. Most recently, blood transfusions have been linked to postoperative wound infections [6], pneumonia [7], renal dysfunction [8], severe sepsis [9], hospital mortality [10], and a poorer prognosis after cancer operations [1113]. Yearly, more than 600,000 cardiac operations are performed on adults in the United States [14]. Bleeding during and after cardiac operation and the hemodilution effects of cardiopulmonary bypass commonly result in blood transfusions [1517]. However, we could not find any studies evaluating the effects of transfusion on long-term survival after cardiac operation. The purpose of this study was to determine if the long-term survival of patients was influenced by transfusions that were done either during or after cardiac operations.


    Material and methods
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 Acknowledgments
 References
 
This study was approved by the Institutional Review Board. Informed consent was waived because it was a retrospective database review. The study was powered to provide a 95% probability of detecting a 30% difference in late mortality between any transfusion and no transfusion groups, assuming a 10% overall mortality and half the patients transfused.

Subjects
All patients who underwent first-time, isolated coronary artery bypass grafting with cardiopulmonary bypass (n = 1,953) between July 6, 1994 and December 31, 1997, were considered for this study. Patients who had valvular, carotid endarterectomy, or other operation simultaneously with coronary artery bypass grafting were excluded, as were redo operations. The start date of the study was chosen as the first date when intraoperative and postoperative transfusions were prospectively separated in the database, whereas the end date was chosen to achieve the power analysis requirements and maintain a minimum 2-year follow-up for all patients. Thirty-five patients (1.8%) with operative mortality (defined by The Society of Thoracic Surgeons as in-hospital death or out-of-hospital death within 30 days of operation) were excluded. Three patients were excluded for missing intraoperative data. The remaining 1,915 patients comprised the study population. All data were prospectively entered into the database. The definitions of The Society of Thoracic Surgeons were used for all entries in the database.

Data analysis
Long-term patient survival data were secured from the United States Social Security Death Index database (http://ssdi.genealogy.rootsweb.com), which was queried in September 2001, using patient name and social security number combinations for all patients. This corresponds to minimum and maximum follow-up times of 39 months (December 1997 patients) and 81 months (July 1994 patients), respectively. Then the database of cardiac operations was updated for all deceased patients with the exact date of death. Then 5-year Kaplan-Meier survival plots were determined and compared for all study subgroups. Hazard functions depicting the rate of death per month for each of the groups were derived from the survival data. These functions are useful to identify the between-group variation in survival trends, and the most critical period determining postoperative survival [18].

Statistical methods
The effect of transfusion on survival was tested in two ways: (1) a two-level approach of transfusion (any) versus no transfusion, and (2) a four-level approach of transfusion (intraoperative only, postoperative only, or both intraoperative and postoperative) versus no transfusion. Thirty-two preoperative, intraoperative, and postoperative variables were analyzed. Univariate analysis for categorical variables was done with either {chi}2 statistic or Fischer’s exact test depending on applicability (Windows Version 8; SAS, Cary, NC). Continuous variables were analyzed using either the unpaired t-test or the nonparametric Mann-Whitney rank sum test depending on normality. A p value less than 0.05 was used to indicate significance.

Next, Cox proportional hazard models were used to explain the affect of explanatory variables (including transfusion) on survival times. Given the biphasic nature (Figs 1 and 2) of the survival, differentiating postoperative year 1 from the succeeding years, these Cox proportional hazard models were applied separately to (1) all patients and (2) only those patients surviving at least 1 year. In either case, model selection was first done with backward elimination, and variables significant at the p less than 0.05 level were retained in the model as independent predictors. The model was then confirmed using forward selection and stepwise selection. After confirming with the two-level approach that any transfusion was a highly significant risk factor for increased mortality, the Cox proportional hazard model was repeated using the four-level approach for the variables.



View larger version (23K):
[in this window]
[in a new window]
 
Fig 1. Kaplan-Meier estimates of survival and hazard functions in the no transfusion (No XFN) and any transfusion (XFN) groups. (A) Five-year (60-month) Kaplan-Meier survival curves in patients transfused versus not transfused. (B) The respective hazard functions for these two groups. (CABG = coronary artery bypass grafting.)

 


View larger version (23K):
[in this window]
[in a new window]
 
Fig 2. Kaplan-Meier estimates of survival and hazard functions in the transfused groups. (A) Five-year (60-month) Kaplan-Meier survival curves for patients who were transfused both intraoperatively and postoperatively (Both), only intraoperatively (Intra-Op), only postoperatively (post-Op), and not transfused (No XFN). (B) The respective hazard functions for these four groups. (CABG = coronary artery bypass grafting.)

 
Because transfusion was not randomly assigned in this patient population, and the concern that multivariate analysis may not adequately control for confounding and bias, the data were further analyzed using propensity scoring. The propensity for transfusion was determined without regard for death using logistic regression analysis. All 32 preoperative, intraoperative, and postoperative variables were entered into the model. Variables were evaluated first univariately, then multivariately. Variables that remained in the model at the p less than 0.05 level were then used to calculate a propensity score for each patient. This propensity score represented the probability that a patient would receive a transfusion. Each transfused patient was then matched to a unique nontransfused patient using propensity scores identical to within 1%. If no match could be achieved at this threshold, the transfused patient was excluded. Five hundred forty-six of 659 transfused patients (83%) were matched.

Then the 1,092 patients matched by propensity scores were analyzed using the previously described Cox proportional hazard model with the two-level approach. The propensity score was forced to remain in the model.


    Results
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 Acknowledgments
 References
 
Six hundred fifty-nine of 1,915 study patients (34%) received a transfusion during their hospitalization. Of these patients, 356 patients (19%) had an intraoperative transfusion, 495 (26%) had a postoperative transfusion, and 192 (10%) had both. Alternatively, isolated intraoperative and postoperative transfusions occurred in 164 patients (9%) and 303 patients (16%), respectively.

We found that transfused patients were older, smaller, and stayed longer in the hospital, and were more likely to be female and to have cerebrovascular disease, peripheral vascular disease, hypertension, higher Society of Thoracic Surgeons (STS) scores, New York Heart Association (NYHA) functional class IV symptoms, and intraaortic balloon pumps. Their operation was more commonly done on an emergency basis and required greater cardiopulmonary bypass time (Table 1). They also had twice the late mortality (15% vs 6%) of nontransfused patients. After correction for comorbidities and other factors, transfusion was still associated with a 70% increase in mortality (risk ratio, 1.7; 95% confidence interval, 1.4 to 2.0; p = 0.001). By multivariate analysis, older age, the presence of peripheral vascular disease (PVD), the presence of chronic obstructive pulmonary disease (COPD), a worse NYHA functional class status, and transfusion were significant predictors of late mortality (Table 2).


View this table:
[in this window]
[in a new window]
 
Table 1. Statistically Significant Characteristics of Patients

 

View this table:
[in this window]
[in a new window]
 
Table 2. Predictors of Total 5-Year Mortality

 
When dividing the transfused group into its 3 subgroups of (1) intraoperative only, (2) postoperative only, and (3) both intraoperative and postoperative, then PVD, COPD, NYHA functional class IV, and older age remained significant predictors of 5-year mortality. Of the three subgroups, the postoperative only group (risk ratio, 1.6; 95% confidence interval, 1.2 to 2.0; p = 0.029) and the both intraoperative and postoperative group (risk ratio, 2.4; 95% confidence interval, 2.0 to 2.8; p < 0.001) were significant predictors of 5-year mortality (Table 3).


View this table:
[in this window]
[in a new window]
 
Table 3. Predictors of Total 5-Year Mortality

 
Kaplan-Meier survival plots suggested both early and late differences in survival with the transfused groups having poorer survival (Fig 1A, 2A). As confirmed by the hazard function (Fig 1B, 2B), there is a biphasic risk of death associated with transfusion. Mortality was several-fold higher in the transfused group for the first several months after operation (Fig 1B); however, by 1 year, mortality had decreased in the transfused group and was now only twice that of the nontransfused group.

After removing the 53 patients who died within 12 months of operation, and reanalyzing the remaining 1,862 patients, transfusion remained a significant predictor of death (risk ratio, 1.5; 95% confidence interval, 1.1 to 1.9; p = 0.04) from 1 to 5 years after operation. By multivariate analysis, older age, the presence of PVD or COPD, NYHA functional class IV status, and transfusion were significant predictors of late mortality (1 to 5 years) (Table 4).


View this table:
[in this window]
[in a new window]
 
Table 4. Predictors of 1- to 5-Year Mortality

 
By subgroup analysis, PVD, COPD, and age remained significant predictors of 1- to 5-year mortality, as were body mass index and both intraoperative and postoperative transfusions (risk ratio, 2.2; 95% confidence interval, 1.7 to 2.8; p = 0.003) (Table 5).


View this table:
[in this window]
[in a new window]
 
Table 5. Predictors at 1- to 5-Year Mortality

 
When the data were reanalyzed using propensity analysis, we found similar results. Predictors of transfusion for the propensity score were older age, female gender, lower weight, longer length of stay, longer perfusion time, and higher STS risk. The 546 transfused patients were well matched to the 546 nontransfused patients (transfused patients and nontransfused patients had a mean ± standard deviation propensity score of 0.576 ± 0.233 and 0.575 ± 0.231, respectively; p = 1.00). Any transfusion compared with no transfusion remained a risk factor for death at follow-up (risk ratio, 1.35; 95% confidence interval, 1.18 to 1.54; p < 0.001) (Fig 3).



View larger version (20K):
[in this window]
[in a new window]
 
Fig 3. Kaplan-Meier estimates of survival based on equal propensity scores of any transfusion (XFN) versus no transfusion (No XFN). (CABG = coronary artery bypass grafting.)

 
Patients with NYHA functional class IV symptoms have a poorer prognosis after a coronary artery bypass graft operation. Even within this group, those who were transfused were more likely to die (Fig 4).



View larger version (32K):
[in this window]
[in a new window]
 
Fig 4. Kaplan-Meier estimates of survival for patients separated into New York Heart Association (NYHA) functional classes I-III and class IV. The inset shows Kaplan-Meier survival for NYHA functional class IV patients transfused intraoperatively only (Intra-Op), postoperatively only (Post-Op), and intraoperatively and postoperatively (Both). (CABG = coronary artery bypass grafting; XFN = transfusion.)

 

    Comment
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 Acknowledgments
 References
 
The primary result of this study showed that transfusion is a risk factor for 5-year mortality after cardiac operation. In addition, we identified several other risk factors for long-term mortality: older age, the presence of peripheral vascular disease, or COPD, and worse cardiac symptoms (NYHA functional class IV). Prior evidence has shown that age [19, 20], peripheral vascular disease [21], and COPD [22] are risk factors for 5-year mortality after coronary artery bypass operations. Severity of anginal symptoms, as measured by NYHA classification, has also been shown to predict late mortality [23]. Transfusion has not been described previously as a risk factor and, unlike the other risk factors, is notable for the fact that it is partially under physician control.

Transfusion with cardiac operations is not inevitable. Lowering the transfusion threshold had no effect on hospital morbidity or mortality [24]. High hematocrits (>= 34%) may even be harmful. Spiess and colleagues [25] found that patients with hematocrits 34% or greater on arrival to the intensive care unit after cardiac operation were more likely to suffer a myocardial infarction and cautioned against transfusion to an arbitrary value. Aprotinin decreased blood transfusion, surgical reexploration for bleeding, and perioperative mortality (odds ratio, 0.55; 95% confidence interval, 0.34 to 0.90) [26]. Using a thromboelastograph to guide coagulation [27], or using a smaller cardiopulmonary bypass circuit or prime volume decreased transfusions [28, 29].

We found that blood transfusion during or after cardiac operation is associated with an increased risk of death over the subsequent 5 years. Although we could not find any previous study that evaluated long-term transfusion risk after cardiac operation, several studies have found transfusion to have short-term deleterious effects after cardiac operation. It increases the risk of nosocomial pneumonia [7], sternal wound infections [6], severe sepsis [9], and renal dysfunction [8]. Utley and colleagues [30] found that transfusion explained the increased perioperative mortality in women. In addition the number of units of blood transfused intraoperatively or on the first postoperative day was a significant predictor of hospital mortality [10]. Using leukocyte-depleted blood for transfusion decreased 60-day mortality after cardiac operation [31]. Defoe and colleagues [32] found that patients who had a lower hematocrit during cardiopulmonary bypass were associated with a higher risk of in-hospital mortality. However they did not provide data on transfusion or try to separate the effect of transfusion versus anemia on in-hospital mortality. They also did not evaluate long-term mortality.

The effects of transfusion on survival after an oncologic operation is controversial, with some studies finding increased mortality in transfused patients [1113] and others finding no difference in mortality [33, 34]. Similar conflicting data were reported by Corry and colleagues, [35] who found decreased survival in patients transfused before undergoing renal transplant, and Solheim and colleagues [36], who found no difference in survival among transfused and nontransfused renal transplant recipients. Both the beneficial effects of transfusion on renal graft survival and the deleterious effects on cancer patients have been attributed to suppression of immune function by an unknown factor in the transfusion. However, blood transfusion given to women during childbirth did not influence the development of malignant tumors, but there was a trend toward higher long-term mortality (22 to 32 years) in the transfused group (5.5 vs 4.2%) [37]. A population-based epidemiological study found that transfusion was an independent predictor of long-term mortality (10 years), with the increased risk being present from all three components of transfusion: packed red cells, fresh frozen plasma, and platelets [38]. Recently a randomized study examined hospital mortality in intensive care unit patients transfused to maintain higher hemoglobin endpoints and found that transfusion was associated with an increased risk of death [39].

The biphasic response we found (ie, a short-term large increase in mortality and then a sustained, long-term increase in mortality in the transfused patients), suggests two separate processes (Fig 1A, 1B). This short-term increase may be caused by the transfusions or the transfusions may be a marker for functionally sicker patients. For example, we may have been more likely to check hemoglobin levels and transfuse patients if they had more dyspnea on exertion from cardiopulmonary dysfunction. Therefore the increased short-term mortality would be caused by the cardiopulmonary dysfunction, and the transfusion would only indicate the marker of a sicker patient. However, with the increased long-term mortality, we find it difficult to hypothesize that transfusion acted as a marker of a sicker patient. In addition there was greater mortality in those patients who received transfusions Both intraoperatively and postoperatively compared with those who received transfusions only intraoperatively or postoperatively (Fig 2A, 2B). Although the number of units transfused was not available, the higher mortality in patients who received transfusions at both times may indicate a dose-dependent relationship.

A limitation of this study is its retrospective nature, which can only find associations and not show causality. Because criterion for transfusion was not established a priori and patients were not randomized to different thresholds for transfusion, transfusion may merely be a marker for sicker, more symptomatic patients. That is, given two patients with equally severe anemia (one symptomatic and transfused and one not symptomatic and therefore not transfused), the increased risk of mortality may be related to the cause of the symptoms, such as worse cardiopulmonary function or muscle deconditioning and not to the transfusion itself. Against this, we found that intraoperative transfusion is a risk factor for increased mortality. In our practice, blood is usually transfused intraoperatively based on hemoglobin levels and not on signs and symptoms.

Another limitation is that hemoglobin levels were not included in the study. Because we routinely do not check hemoglobin levels more than 24 hours postoperatively, but check it only as clinically indicated (eg, elevated sanguineous chest tube drainage, pallor, or dyspnea), including hemoglobin levels would have introduced a bias. Because virtually all patients who died in-hospital or within 30 days of operation received transfusions, we eliminated these patients from the study. Including them would have overestimated the risk of blood transfusions. A fourth limitation is that we examined all-cause mortality and were unable to determine the cause of death (cardiac or noncardiac). Although death certificates may have been helpful, they may be less than accurate in the absence of autopsies. A final limitation is that while the study was designed to look for and did find a difference in mortality between transfused and nontransfused patients, the study may have been underpowered for the four-group analysis.

In conclusion, we found that transfusing blood during or after cardiac operation is associated with an increased 5-year mortality.


    Acknowledgments
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 Acknowledgments
 References
 
Supported by institutional and departmental funds.


    References
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 Acknowledgments
 References
 

  1. Wallace E.L., Churchill W.H., Surgenor D.M., Cho G.S., McGurk S. Collection and transfusion of blood and blood components in the United States, 1994. Transfusion 1998;38:625-636.[Medline]
  2. Hebert P.C., Wells G., Martin C., et al. A Canadian survey of transfusion practices in critically ill patients. Crit Care Med 1998;26:482-487.[Medline]
  3. Hebert P.C., Schweitzer I., Calder L., Blajchman M., Giulivi A. Review of the clinical practice literature on allogeneic red blood cell transfusion. Can Med Assoc J 1997;156:S9-S26.
  4. Barton J.C. Nonhemolytic, noninfectious transfusions reactions. Semin Hematol 1981;18:95-121.[Medline]
  5. Schreiber G.B., Busch M.P., Kleinman S.H., Korelitz J.J. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334:1685-1690.[Medline]
  6. Zacharias A., Habib R.H. Factors predisposing to median sternotomy complications. Deep vs superficial infection. Chest 1996;110:1173-1178.[Medline]
  7. Leal-Noval S.R., Marquez-Vácaro J.A., Garcia-Curiel A., et al. Nosocomial pneumonia in patients undergoing heart surgery. Crit Care Med 2000;28:935-940.
  8. Ranucci M., Pavesi M., Mazza E., et al. Risk factors for renal dysfunction after coronary surgery: the role of cardiopulmonary bypass technique. Perfusion 1994;9:319-326.[Abstract/Free Full Text]
  9. Michalopoulos A., Stavridis G., Geroulanos S. Severe sepsis in cardiac surgical patients. Eur J Surg 1998;164:217-222.[Medline]
  10. Michalopoulos A., Tzelepis G., Dafni U., Geroulanos S. Determinants of hospital mortality after coronary artery bypass grafting. Chest 1999;115:1598-1603.[Medline]
  11. Burrows L., Tartter P. Effect of blood transfusions on colonic malignancy recurrence rate. Lancet 1982;ii:662.
  12. Tachibana M., Kinugasa S., Dhar D.K. Prognostic factors after extended esophagectomy for squamous cell carcinoma of the thoracic esophagus. J Surg Oncol 1999;72:88-93.[Medline]
  13. Asahara T., Katayama K., Itamoto T., et al. Perioperative blood transfusion as a prognostic indicator in patients with hepatocellular carcinoma. World J Surg 1999;23:676-680.[Medline]
  14. 2000 Heart and stroke statistical update. Dallas, TX: American Heart Association, 1999:26.
  15. Knutson J.E., Deering J.A., Hall F.W., et al. Does intraoperative hetastarch administration increase blood loss and transfusion requirements after cardiac surgery?. Anesth Analg 2000;90:801-807.[Abstract/Free Full Text]
  16. Dietrich W., Lüth J.U., Kormann J., et al. Intraoperativer fremdblutverblauch und eigenbluttransfusion in der kardioanästhesie. Anaesthesist 1999;48:876-883.[Medline]
  17. Shore-Lesserson L., Manspeizer H.E., Bolastig M., Harrington D., Vela-Cantos F., DePerio M. Anticoagulation for cardiac surgery in patients receiving preoperative heparin: use of the high-dose thrombin time. Anesth Analg 2000;90:813-818.[Abstract/Free Full Text]
  18. Kirklin J.W., Barratt-Boyes B.G. The generation of knowledge from information, data, and analyses. Cardiac surgery, vol. 1 (Morphology, diagnostic criteria, natural history, techniques, results, and indications), 2nd ed New York: Churchill Livingstone Inc, 1993:249-282.
  19. Herlitz J., Brandrup-Wognsen G., Karlson B.W., et al. Mortality, risk indicators for death, and mode of death in younger and elderly patients during five years after coronary artery bypass graft. Clin Cardiol 2000;23:421-426.[Medline]
  20. Davila-Roman V.G., Murphy S.F., Nickerson N.J., Kouchoukos N.T., Schechtman K.B., Barzilai B. Atherosclerosis of the ascending aorta is an independent predictor of long-term neurologic events and mortality. J Am Coll Cardiol 1999;33:1308-1316.[Medline]
  21. Birkmeyer J.D., Quinton H.B., O’Connor N.J., et al. The effect of peripheral vascular disease on long-term mortality after cardiac artery bypass surgery. Arch Surg 1996;131:316-321.[Medline]
  22. Brooks M.M., Jones R.H., Bach R.G., et al. Predictors of mortality and mortality from cardiac causes in the bypass angioplasty revascularization investigation (BARI) randomized trial and registry. Circulation 2000;101:2682-2689.[Abstract/Free Full Text]
  23. Trachiotis G.D., Weintraub W.S., Johnston T.S., Jones E.L., Guyton R.A., Craver J.M. Coronary artery bypass grafting in patients with advanced left ventricular dysfunction. Ann Thorac Surg 1998;66:1632-1639.[Abstract/Free Full Text]
  24. Bracey A.W., Radovancevic R., Riggs S.A., et al. Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome. Transfusion 1999;39:1070-1077.[Medline]
  25. Spiess B.D., Ley C., Body S.C., et al. Hematocrit value on intensive care unit entry influences the frequency of Q-wave myocardial infarction after coronary artery bypass grafting. J Thorac Cardiovasc Surg 1998;116:460-467.[Abstract/Free Full Text]
  26. Levi M., Cromheecke M.E., de Jonge E., et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999;354:1940-1947.[Medline]
  27. Spiess B.D., Gillies B.S.A., Chandler W., Verrier E. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgery patients. J Cardiothorac Vasc Anesth 1995;9:168-173.[Medline]
  28. Cormack J.E., Forest R.J., Groom R.C., Morton J. Size makes a difference: use of a low-prime cardiopulmonary bypass circuit and autologous priming in small adults. Perfusion 2000;15:129-135.[Abstract/Free Full Text]
  29. Shapira O.M., Aldea G.S., Treanor P.R., et al. Reduction of allogeneic blood transfusions after open heart operations by lowering cardiopulmonary bypass prime volume. Ann Thorac Surg 1998;65:724-730.[Abstract/Free Full Text]
  30. Utley J.R., Wilde E.F., Leyland S.A., Morgan M.S., Johnson H.D. Intraoperative blood transfusion is a major risk factor for coronary artery bypass grafting in women. Ann Thorac Surg 1995;60:570-574.[Abstract/Free Full Text]
  31. van de Watering L.M., Hermans J., Houbiers J.G., et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998;97:562-568.[Abstract/Free Full Text]
  32. DeFoe G.R., Ross C.F., Olmstead E.M., et al. Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Ann Thorac Surg 2001;71:769-776.[Abstract/Free Full Text]
  33. Nathanson S.D., Tilley B.C., Schultz L., Smith R.F. Perioperative allogenic blood transfusions. Survival in patients with resected carcinomas of the colon and rectum. Arch Surg 1985;120:734-738.[Medline]
  34. Garau I., Benito E., Bosch F.X., et al. Blood transfusion has no effect on colorectal cancer survival. A population-based study. Eur J Cancer 1994;30A:759-764.[Medline]
  35. Corry R.J., West J.C., Hunsicker L.G., Schanbacher B.A., Lachenbruch P.A. Effect of timing of administration and quantity of blood transfusion on cadaver renal transplant survival. Transplantation 1980;30:425-428.[Medline]
  36. Solheim B.G., Flatmark A., Halvorsen S., Jervell J., Pape J., Thorsby E. Effect of blood transfusions on renal transplantation: study of 191 consecutive first transplants from living related donors. Transplantation 1980;30:281-284.[Medline]
  37. Sknberg J., Frisk B. Blood transfusion does not influence the development of malignant tumours. Eur J Surg 1999;165:528-534.[Medline]
  38. Vamvakas E.C., Taswell H.F. Long-term survival after blood transfusion. Transfusion 1994;34:471-477.[Medline]
  39. Hebert P.C., Wells G., Blajchman M.A., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. New Engl J Med 1999;340:409-417.[Medline]



This article has been cited by other articles:


Home page
Interact CardioVasc Thorac SurgHome page
R. Warwick, N. Mediratta, J. Chalmers, M. Pullan, M. Shaw, J. Mcshane, and M. Poullis
Is single-unit blood transfusion bad post-coronary artery bypass surgery?
Interact CardioVasc Thorac Surg, June 1, 2013; 16(6): 765 - 771.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
S.-F. Zhou, A. L. Estrera, C. C. Miller III, C. Ignacio, S. Panthayi, P. Loubser, D. L. Sagun, R. Sheinbaum, and H. J. Safi
Analysis of Autologous Platelet-Rich Plasma During Ascending and Transverse Aortic Arch Surgery
Ann. Thorac. Surg., May 1, 2013; 95(5): 1525 - 1530.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
P. Sun, B. Ji, Y. Sun, X. Zhu, J. Liu, C. Long, and Z. Zheng
Effects of retrograde autologous priming on blood transfusion and clinical outcomes in adults: a meta-analysis
Perfusion, May 1, 2013; 28(3): 238 - 243.
[Abstract] [Full Text] [PDF]


Home page
Interact CardioVasc Thorac SurgHome page
G. Scrascia, C. Rotunno, P. Guida, M. Conte, L. Amorese, V. Margari, L. d. L. T. Schinosa, and D. Paparella
Haemostasis alterations in coronary artery bypass grafting: comparison between the off-pump technique and a closed coated cardiopulmonary bypass system
Interact CardioVasc Thorac Surg, May 1, 2013; 16(5): 636 - 642.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
S. Matsuda, T. Fukui, J. Shimizu, A. Takao, S. Takanashi, and H. Tomoike
Associations Between Preoperative Anemia and Outcomes After Off-Pump Coronary Artery Bypass Grafting
Ann. Thorac. Surg., March 1, 2013; 95(3): 854 - 860.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
D. J. LaPar, I. K. Crosby, G. Ailawadi, N. Ad, E. Choi, B. D. Spiess, J. B. Rich, V. Kasirajan, E. Fonner Jr., I. L. Kron, et al.
Blood product conservation is associated with improved outcomes and reduced costs after cardiac surgery
J. Thorac. Cardiovasc. Surg., March 1, 2013; 145(3): 796 - 804.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
M. Chu, K. Losenno, K. Moore, D. Berta, J. Hewitt, and F. Ralley
Blood conservation strategies reduce the need for transfusions in ascending and aortic arch surgery
Perfusion, February 22, 2013; (2013) 0267659113479816v1.
[Abstract] [Full Text] [PDF]


Home page
Eur J Cardiothorac SurgHome page
T. A. Schwann, L. Al-Shaar, M. Engoren, and R. H. Habib
Late effects of radial artery vs saphenous vein grafting for multivessel coronary bypass surgery in diabetics: a propensity-matched analysis
Eur J Cardiothorac Surg, February 21, 2013; (2013) ezt061v1.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
A. El-Essawi, I. Breitenbach, K. Ali, P. Jungebluth, R. Brouwer, M. Anssar, and W. Harringer
Minimized perfusion circuits: an alternative in the surgical treatment of Jehovah's Witnesses
Perfusion, January 1, 2013; 28(1): 47 - 53.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. J. Yun, R. E. Helm, R. S. Kramer, B. J. Leavitt, S. D. Surgenor, A. W. DiScipio, L. J. Dacey, Y. R. Baribeau, L. Russo, G. L. Sardella, et al.
Limited Blood Transfusion Does Not Impact Survival in Octogenarians Undergoing Cardiac Operations
Ann. Thorac. Surg., December 1, 2012; 94(6): 2038 - 2045.
[Abstract] [Full Text] [PDF]


Home page
Interact CardioVasc Thorac SurgHome page
J. Nilsson, S. Scicluna, G. Malmkvist, L. Pierre, L. Algotsson, P. Paulsson, H. Bjursten, and P. Johnsson
A randomized study of coronary artery bypass surgery performed with the Resting Heart™ System utilizing a low vs a standard dosage of heparin
Interact CardioVasc Thorac Surg, November 1, 2012; 15(5): 834 - 839.
[Abstract] [Full Text] [PDF]


Home page
Asian Cardiovascular and Thoracic AnnalsHome page
N. L. Tan, H. Corbineau, B. D. Phu, and J.-P. Verhoye
Is a cell saver necessary in off-pump coronary artery bypass surgery?
Asian Cardiovascular and Thoracic Annals, October 1, 2012; 20(5): 539 - 543.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
T. J. George, C. A. Beaty, A. Kilic, K. A. Haggerty, S. M. Frank, W. J. Savage, and G. J. Whitman
Hemoglobin Drift After Cardiac Surgery
Ann. Thorac. Surg., September 1, 2012; 94(3): 703 - 709.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
B. Bhaskar, J. Dulhunty, D. V. Mullany, and J. F. Fraser
Impact of Blood Product Transfusion on Short and Long-Term Survival After Cardiac Surgery: More Evidence
Ann. Thorac. Surg., August 1, 2012; 94(2): 460 - 467.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. Redlin, H. Habazettl, W. Boettcher, M. Kukucka, H. Schoenfeld, R. Hetzer, and M. Huebler
Effects of a comprehensive blood-sparing approach using body weight-adjusted miniaturized cardiopulmonary bypass circuits on transfusion requirements in pediatric cardiac surgery
J. Thorac. Cardiovasc. Surg., August 1, 2012; 144(2): 493 - 499.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
G. Scrascia, C. Rotunno, D. Nanna, R. Rociola, P. Guida, G. Rubino, L. de Luca Tupputi Schinosa, and D. Paparella
Pump blood processing, salvage and re-transfusion improves hemoglobin levels after coronary artery bypass grafting, but affects coagulative and fibrinolytic systems
Perfusion, July 1, 2012; 27(4): 270 - 277.
[Abstract] [PDF]


Home page
Eur J Cardiothorac SurgHome page
C.-J. Jakobsen, P. K. Ryhammer, M. Tang, J. J. Andreasen, and P. E. Mortensen
Transfusion of blood during cardiac surgery is associated with higher long-term mortality in low-risk patients
Eur J Cardiothorac Surg, July 1, 2012; 42(1): 114 - 120.
[Abstract] [Full Text] [PDF]


Home page
J Intensive Care MedHome page
M. Engoren
The Effect of Red Blood Cell Transfusion on 90-day Mortality in Patients With Acute Lung Injury
J Intensive Care Med, March 1, 2012; 27(2): 112 - 118.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
D. Bianchi, R. G. Alvarez, A. A. Motos, D. S. Duenas, L. G. Montero, J. M. C. Vecino, U. Paralkar, S. Vamadevan, G. Lawton, S.-H. Kim, et al.
EQUIPMENT, MONITORING, AND ENGINEERING TECHNOLOGY
Br. J. Anaesth., March 1, 2012; 108(suppl_2): ii109 - ii144.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
G. Paone, R. Brewer, P. F. Theurer, G. F. Bell, C. M. Cogan, R. L. Prager, and Michigan Society of Thoracic and Cardiovascular Su
Preoperative predicted risk does not fully explain the association between red blood cell transfusion and mortality in coronary artery bypass grafting
J. Thorac. Cardiovasc. Surg., January 1, 2012; 143(1): 178 - 185.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
H. J. Ipema and M. G. Tanzi
Use of Topical Tranexamic Acid or Aminocaproic Acid to Prevent Bleeding After Major Surgical Procedures
Ann. Pharmacother., January 1, 2012; 46(1): 97 - 107.
[Abstract] [Full Text] [PDF]


Home page
Eur J Cardiothorac SurgHome page
A. J. Chapman, A. L. Blount, A. T. Davis, and R. L. Hooker
Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery
Eur J Cardiothorac Surg, December 1, 2011; 40(6): 1314 - 1319.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. Redlin, M. Huebler, W. Boettcher, M. Kukucka, H. Schoenfeld, R. Hetzer, and H. Habazettl
Minimizing intraoperative hemodilution by use of a very low priming volume cardiopulmonary bypass in neonates with transposition of the great arteries
J. Thorac. Cardiovasc. Surg., October 1, 2011; 142(4): 875 - 881.
[Abstract] [Full Text] [PDF]


Home page
American Journal of Medical QualityHome page
F. Masud, K. Larson-Pollock, C. Leveque, and D. Vykoukal
Establishing a Culture of Blood Management Through Education: A Quality Initiative Study of Postoperative Blood Use in CABG Patients at Methodist DeBakey Heart & Vascular Center
American Journal of Medical Quality, September 1, 2011; 26(5): 349 - 356.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. Ranucci, S. Aronson, W. Dietrich, C. M. Dyke, A. Hofmann, K. Karkouti, M. Levi, G. J. Murphy, F. W. Sellke, L. Shore-Lesserson, et al.
Patient blood management during cardiac surgery: Do we have enough evidence for clinical practice?
J. Thorac. Cardiovasc. Surg., August 1, 2011; 142(2): 249.e1 - 249.e32.
[Full Text] [PDF]


Home page
The OncologistHome page
A. Hofmann, S. Farmer, and A. Shander
Five Drivers Shifting the Paradigm from Product-Focused Transfusion Practice to Patient Blood Management
Oncologist, August 1, 2011; 16(suppl_3): 3 - 11.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. Ranucci, M. T. La Rovere, S. Castelvecchio, R. Maestri, L. Menicanti, A. Frigiola, A. M. D'Armini, C. Goggi, R. Tramarin, and O. Febo
Postoperative Anemia and Exercise Tolerance After Cardiac Operations in Patients Without Transfusion: What Hemoglobin Level Is Acceptable?
Ann. Thorac. Surg., July 1, 2011; 92(1): 25 - 31.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
G. Yarham, A. Clements, M. Oliver, C. Morris, T. Cumberland, M. Bryan, S. Jekler, K. Johns, and J. Mulholland
Evaluating the 'next generation' of cell salvage - will it make a difference?
Perfusion, July 1, 2011; 26(4): 263 - 270.
[Abstract] [PDF]


Home page
Br J AnaesthHome page
M. McKenny, T. Ryan, H. Tate, B. Graham, V. K. Young, and N. Dowd
Age of transfused blood is not associated with increased postoperative adverse outcome after cardiac surgery
Br. J. Anaesth., May 1, 2011; 106(5): 643 - 649.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. M. Schaffer, G. J. Arnaoutakis, J. G. Allen, E. S. Weiss, N. D. Patel, S. D. Russell, A. S. Shah, and J. V. Conte
Bleeding Complications and Blood Product Utilization With Left Ventricular Assist Device Implantation
Ann. Thorac. Surg., March 1, 2011; 91(3): 740 - 749.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
V. A. Ferraris, J. R. Brown, G. J. Despotis, J. W. Hammon, T. B. Reece, S. P. Saha, H. K. Song, E. R. Clough, L. J. Shore-Lesserson, L. T. Goodnough, et al.
2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines
Ann. Thorac. Surg., March 1, 2011; 91(3): 944 - 982.
[Abstract] [Full Text] [PDF]


Home page
Eur J Cardiothorac SurgHome page
J. J. Andreasen, C. Dethlefsen, I. S. Modrau, J. Baech, H. C. Schonheyder, J. K. Moeller, S. P. Johnsen, and for the North-West Denmark Transfusion Study Group
Storage time of allogeneic red blood cells is associated with risk of severe postoperative infection after coronary artery bypass grafting
Eur J Cardiothorac Surg, March 1, 2011; 39(3): 329 - 334.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
A. H. M. van Straten, M. A. Soliman Hamad, A. A. J. van Zundert, E. J. Martens, J. F. ter Woorst, A. M. de Wolf, and V. Scharnhorst
Effect of duration of red blood cell storage on early and late mortality after coronary artery bypass grafting
J. Thorac. Cardiovasc. Surg., January 1, 2011; 141(1): 231 - 237.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
A. H. M. van Straten, M. A. Soliman Hamad, E. J. Martens, M. E. S. H. Tan, A. M. de Wolf, V. Scharnhorst, and A. A. J. van Zundert
Effect of storage time of transfused plasma on early and late mortality after coronary artery bypass grafting
J. Thorac. Cardiovasc. Surg., January 1, 2011; 141(1): 238 - 243.e2.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
D. Fitzgerald, A. Ging, N. Burton, S. Desai, T. Elliott, and L. Edwards
The use of percutaneous ECMO support as a 'bridge to bridge' in heart failure patients: a case report
Perfusion, September 1, 2010; 25(5): 321 - 325.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
D. M. Moskowitz, J. N. McCullough, A. Shander, J. J. Klein, C. A. Bodian, R. S. Goldweit, and M. A. Ergin
The Impact of Blood Conservation on Outcomes in Cardiac Surgery: Is It Safe and Effective?
Ann. Thorac. Surg., August 1, 2010; 90(2): 451 - 458.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. Engoren
Invited Commentary
Ann. Thorac. Surg., August 1, 2010; 90(2): 458 - 459.
[Full Text] [PDF]


Home page
American Journal of Medical QualityHome page
J. Morton, K. P. Anastassopoulos, S. T. Patel, J. H. Lerner, K. J. Ryan, T. F. Goss, and S. L. Dodd
Frequency and Outcomes of Blood Products Transfusion Across Procedures and Clinical Conditions Warranting Inpatient Care: An Analysis of the 2004 Healthcare Cost and Utilization Project Nationwide Inpatient Sample Database
American Journal of Medical Quality, July 1, 2010; 25(4): 289 - 296.
[Abstract] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
K. Kellermann and B. Jungwirth
Avoiding Stroke During Cardiac Surgery
Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2010; 14(2): 95 - 101.
[Abstract] [PDF]


Home page
World Journal for Pediatric and Congenital Heart SurgeryHome page
K. G. Shann, C. R. Giacomuzzi, J. P. Jacobs, G. J. Myers, T. A. Paugh, N. Mellas, L. Puis, J. W. Ojito, D. Gomez, V. Olshove, et al.
Rationale and Use of Perfusion Variables in the 2010 Update of the Society of Thoracic Surgeons Congenital Heart Surgery Database
World Journal for Pediatric and Congenital Heart Surgery, April 1, 2010; 1(1): 34 - 43.
[Abstract] [Full Text] [PDF]


Home page
Interact CardioVasc Thorac SurgHome page
Y. Carrascal, L. Maroto, J. Rey, A. Arevalo, J. Arroyo, J. R. Echevarria, N. Arce, and E. Fulquet
Impact of preoperative anemia on cardiac surgery in octogenarians
Interact CardioVasc Thorac Surg, February 1, 2010; 10(2): 249 - 255.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. Ranucci, D. Conti, S. Castelvecchio, L. Menicanti, A. Frigiola, A. Ballotta, and G. Pelissero
Hematocrit on Cardiopulmonary Bypass and Outcome After Coronary Surgery in Nontransfused Patients
Ann. Thorac. Surg., January 1, 2010; 89(1): 11 - 17.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. Engoren
Invited Commentary
Ann. Thorac. Surg., January 1, 2010; 89(1): 18 - 18.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
S. L. Rohde, R. A. Baker, P. J. Tully, S. Graham, H. Cullen, and J. L. Knight
Preoperative and Intraoperative Factors Associated With Long-Term Survival in Octogenarian Cardiac Surgery Patients
Ann. Thorac. Surg., January 1, 2010; 89(1): 105 - 111.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
L. H. Edmunds Jr
Managing Fibrinolysis Without Aprotinin
Ann. Thorac. Surg., January 1, 2010; 89(1): 324 - 331.
[Abstract] [Full Text] [PDF]


Home page
Interact CardioVasc Thorac SurgHome page
A. H. M. van Straten, M. W. A. Bekker, M. A. Soliman Hamad, A. A. J. van Zundert, E. J. Martens, J. P. A. M. Schonberger, and A. M. de Wolf
Transfusion of red blood cells: the impact on short-term and long-term survival after coronary artery bypass grafting, a ten-year follow-up
Interact CardioVasc Thorac Surg, January 1, 2010; 10(1): 37 - 42.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
S. Senay, F. Toraman, H. Karabulut, and C. Alhan
Is it the patient or the physician who cannot tolerate anemia? A prospective analysis in 1854 non-transfused coronary artery surgery patients
Perfusion, November 1, 2009; 24(6): 373 - 380.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. C. Christensen, S. Krapf, A. Kempel, and C. von Heymann
Costs of excessive postoperative hemorrhage in cardiac surgery
J. Thorac. Cardiovasc. Surg., September 1, 2009; 138(3): 687 - 693.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
R. A. J. M. Huybregts, R. de Vroege, E. K. Jansen, A. W. van Schijndel, H. M. T. Christiaans, and W. van Oeveren
The Association of Hemodilution and Transfusion of Red Blood Cells with Biochemical Markers of Splanchnic and Renal Injury During Cardiopulmonary Bypass
Anesth. Analg., August 1, 2009; 109(2): 331 - 339.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Gill, M. Herbertson, A. Vuylsteke, P. S. Olsen, C. von Heymann, M. Mythen, F. Sellke, F. Booth, and T. A. Schmidt
Safety and Efficacy of Recombinant Activated Factor VII: A Randomized Placebo-Controlled Trial in the Setting of Bleeding After Cardiac Surgery
Circulation, July 7, 2009; 120(1): 21 - 27.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. Engoren, R. H. Habib, J. Hadaway, A. Zacharias, T. A. Schwann, C. J. Riordan, S. J. Durham, and A. Shah
The Effect on Long-Term Survival of Erythrocyte Transfusion Given for Cardiac Valve Operations
Ann. Thorac. Surg., July 1, 2009; 88(1): 95 - 100.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
S. D. Surgenor, R. S. Kramer, E. M. Olmstead, C. S. Ross, F. W. Sellke, D. S. Likosky, C. A. S. Marrin, R. E. Helm Jr, B. J. Leavitt, J. R. Morton, et al.
The Association of Perioperative Red Blood Cell Transfusions and Decreased Long-Term Survival After Cardiac Surgery
Anesth. Analg., June 1, 2009; 108(6): 1741 - 1746.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
G. S. Murphy, E. A. Hessel II, and R. C. Groom
Optimal Perfusion During Cardiopulmonary Bypass: An Evidence-Based Approach
Anesth. Analg., May 1, 2009; 108(5): 1394 - 1417.
[Abstract] [Full Text] [PDF]


Home page
Am J Crit CareHome page
M. Engoren and C. Arslanian-Engoren
Long-term Survival in the Intensive Care Unit After Erythrocyte Blood Transfusion
Am. J. Crit. Care., March 1, 2009; 18(2): 124 - 131.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. Brevig, J. McDonald, E. S. Zelinka, T. Gallagher, R. Jin, and G. L. Grunkemeier
Blood Transfusion Reduction in Cardiac Surgery: Multidisciplinary Approach at a Community Hospital
Ann. Thorac. Surg., February 1, 2009; 87(2): 532 - 539.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
R Rimpilainen, F Biancari, J. Wistbacka, P Loponen, S. Koivisto, J Rimpilainen, K Teittinen, and J Nissinen
Outcome after coronary artery bypass surgery with miniaturized versus conventional cardiopulmonary bypass
Perfusion, November 1, 2008; 23(6): 361 - 367.
[Abstract] [PDF]


Home page
Anesth. Analg.Home page
G. M. T. Hare, A. K. Y. Tsui, A. T. McLaren, T. E. Ragoonanan, J. Yu, and C. D. Mazer
Anemia and Cerebral Outcomes: Many Questions, Fewer Answers
Anesth. Analg., October 1, 2008; 107(4): 1356 - 1370.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
G. Lindvall, U. Sartipy, T. Ivert, and J. van der Linden
Aprotinin is Not Associated With Postoperative Renal Impairment After Primary Coronary Surgery
Ann. Thorac. Surg., July 1, 2008; 86(1): 13 - 19.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. Dunning, J. R.L. Waller, B. Smith, S. Pitts, S. W.H. Kendall, and K. Khan
Coronary Artery Bypass Grafting is Associated With Excellent Long-Term Survival and Quality of Life: A Prospective Cohort Study
Ann. Thorac. Surg., June 1, 2008; 85(6): 1988 - 1993.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
L. J. Bowman, W. E. Uber, M. R. Stroud, L. R. Christiansen, J. Lazarchick, A. J. Crumbley III, J. M. Kratz, J. M. Toole, F. A. Crawford Jr, and J. S. Ikonomidis
Use of Recombinant Activated Factor VII Concentrate to Control Postoperative Hemorrhage in Complex Cardiovascular Surgery
Ann. Thorac. Surg., May 1, 2008; 85(5): 1669 - 1677.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
S. Dunkley, L. Phillips, P. McCall, J. Brereton, R. Lindeman, G. Jankelowitz, and P. Cameron
Recombinant Activated Factor VII in Cardiac Surgery: Experience From the Australian and New Zealand Haemostasis Registry
Ann. Thorac. Surg., March 1, 2008; 85(3): 836 - 844.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
D. Pagano, N. J. Howell, N. Freemantle, D. Cunningham, R. S. Bonser, T. R. Graham, J. Mascaro, S. J. Rooney, I. C. Wilson, R. Cramb, et al.
Bleeding in cardiac surgery: The use of aprotinin does not affect survival
J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 495 - 502.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
A. Rigamonti, A. T. McLaren, C. D. Mazer, K. Nix, T. Ragoonanan, J. Freedman, A. Harrington, and G. M. T. Hare
Storage of strain-specific rat blood limits cerebral tissue oxygen delivery during acute fluid resuscitation
Br. J. Anaesth., March 1, 2008; 100(3): 357 - 364.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J.F. M. Bechtel, C. Detter, T. Fischlein, T. Krabatsch, B. R. Osswald, F.-C. Riess, F. Scholz, M. Schonburg, C. Stamm, H.-H. Sievers, et al.
Cardiac Surgery in Patients on Dialysis: Decreased 30-Day Mortality, Unchanged Overall Survival
Ann. Thorac. Surg., January 1, 2008; 85(1): 147 - 153.
[Abstract] [Full Text] [PDF]


Home page
Card Surg AdultHome page
Z. I. Khalpey, R. B. Ganim, and J. D. Rawn
Postoperative Care of Cardiac Surgery Patients
, January 1, 2008; 3(2008): 465 - 486.
[Full Text]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
F. E. Ralley
Programmatic Blood Conservation in Cardiac Surgery
Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2007; 11(4): 242 - 246.
[Abstract] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
A. F. Merry
Focus on Thrombin: Alternative Anticoagulants
Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2007; 11(4): 256 - 260.
[Abstract] [PDF]


Home page
CirculationHome page
J. D. Rawn
Blood Transfusion in Cardiac Surgery: A Silent Epidemic Revisited
Circulation, November 27, 2007; 116(22): 2523 - 2524.
[Full Text] [PDF]


Home page
Br J AnaesthHome page
P. J. Van der Linden, J.-F. Hardy, A. Daper, A. Trenchant, and S. G. De Hert
Cardiac surgery with cardiopulmonary bypass: does aprotinin affect outcome?
Br. J. Anaesth., November 1, 2007; 99(5): 646 - 652.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
K. Charette, Y. Hirata, A. Bograd, L. Mongero, J. Chen, J. Quaegebeur, and R. Mosca
180 ml and less: Cardiopulmonary bypass techniques to minimize hemodilution for neonates and small infants
Perfusion, September 1, 2007; 22(5): 327 - 331.
[Abstract] [PDF]


Home page
CirculationHome page
T. J. Gardner
To Transfuse or Not to Transfuse
Circulation, July 31, 2007; 116(5): 458 - 460.
[Full Text] [PDF]


Home page
Eur J Cardiothorac SurgHome page
M. Perthel, L. El-Ayoubi, A. Bendisch, J. Laas, and M. Gerigk
Clinical advantages of using mini-bypass systems in terms of blood product use, postoperative bleeding and air entrainment: an in vivo clinical perspective
Eur J Cardiothorac Surg, June 1, 2007; 31(6): 1070 - 1075.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al.
Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline
Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86.
[Abstract] [Full Text] [PDF]


Home page
Am J Crit CareHome page
S. Gould, M. J. Cimino, and D. R. Gerber
Packed Red Blood Cell Transfusion in the Intensive Care Unit: Limitations and Consequences
Am. J. Crit. Care., January 1, 2007; 16(1): 39 - 48.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
M. Perthel, A. Klingbeil, L. El-Ayoubi, M. Gerick, and J. Laas
Reduction in blood product usage associated with routine use of mini bypass systems in extracorporeal circulation
Perfusion, January 1, 2007; 22(1): 9 - 14.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
G. J. Murphy and G. D. Angelini
Indications for Blood Transfusion in Cardiac Surgery
Ann. Thorac. Surg., December 1, 2006; 82(6): 2323 - 2334.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
G. J. Murphy, E. Mango, V. Lucchetti, F. Battaglia, D. Catapano, C. A. Rogers, and G. D. Angelini
A randomized trial of tranexamic acid in combination with cell salvage plus a meta-analysis of randomized trials evaluating tranexamic acid in off-pump coronary artery bypass grafting.
J. Thorac. Cardiovasc. Surg., September 1, 2006; 132(3): 475 - 480.e8.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
K. G. Shann, D. S. Likosky, J. M. Murkin, R. A. Baker, Y. R. Baribeau, G. R. DeFoe, T. A. Dickinson, T. J. Gardner, H. P. Grocott, G. T. O'Connor, et al.
An evidence-based review of the practice of cardiopulmonary bypass in adults: A focus on neurologic injury, glycemic control, hemodilution, and the inflammatory response.
J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 283 - 290.e3.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
C. G. Koch, F. Khandwala, L. Li, F. G. Estafanous, F. D. Loop, and E. H. Blackstone
Persistent Effect of Red Cell Transfusion on Health-Related Quality of Life After Cardiac Surgery
Ann. Thorac. Surg., July 1, 2006; 82(1): 13 - 20.
[Abstract] [Full Text] [PDF]


Home page
American Journal of Medical QualityHome page
A. DeAnda Jr, K. M. Baker, S. D. Roseff, J. A. Green, H. Mccarthy, T. Aron, and B. D. Spiess
Developing a Blood Conservation Program in Cardiac Surgery
American Journal of Medical Quality, July 1, 2006; 21(4): 230 - 237.
[Abstract] [PDF]


Home page
PerfusionHome page
T. Jones and M. Elliott
Paediatric CPB: Bypass in a High Risk Group
Perfusion, July 1, 2006; 21(4): 229 - 233.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
C. G. Koch, L. Li, A. I. Duncan, T. Mihaljevic, F. D. Loop, N. J. Starr, and E. H. Blackstone
Transfusion in Coronary Artery Bypass Grafting is Associated with Reduced Long-Term Survival.
Ann. Thorac. Surg., May 1, 2006; 81(5): 1650 - 1657.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. I. Kapetanakis, D. A. Medlam, K. R. Petro, E. Haile, P. C. Hill, M. K.C. Dullum, A. S. Bafi, S. W. Boyce, and P. J. Corso
Effect of Clopidogrel Premedication in Off-Pump Cardiac Surgery: Are We Forfeiting the Benefits of Reduced Hemorrhagic Sequelae?
Circulation, April 4, 2006; 113(13): 1667 - 1674.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
S Purkayastha, T Athanasiou, V Malinovski, P Tekkis, R Foale, R Casula, B Glenville, and A Darzi
Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis.
Heart, April 1, 2006; 92(4): 531 - 532.
[Full Text] [PDF]


Home page
Anesth. Analg.Home page
L. T. Goodnough, A. Shander, J. L. Spivak, J. H. Waters, A. J. Friedman, J. L. Carson, E. M. Keating, T. Maddox, and R. Spence
Detection, Evaluation, and Management of Anemia in the Elective Surgical Patient
Anesth. Analg., December 1, 2005; 101(6): 1858 - 1861.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
P. Diprose, M. J. Herbertson, D. O'Shaughnessy, and R. S. Gill
Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study
Br. J. Anaesth., November 1, 2005; 95(5): 596 - 602.
[Abstract] [Full Text] [PDF]


Home page
Eur J Cardiothorac SurgHome page
R. H. Habib, A. Zacharias, T. A. Schwann, and C. J. Riordan
The independent effects of cardiopulmonary bypass hemodilutional anemia and transfusions on CABG outcomes
Eur J Cardiothorac Surg, September 1, 2005; 28(3): 512 - 513.
[Full Text] [PDF]


Home page
Eur J Cardiothorac SurgHome page
M. Kuduvalli, A. D. Grayson, M. J. Desmond, and B. M. Fabri
Reply to Habib et al.
Eur J Cardiothorac Surg, September 1, 2005; 28(3): 513 - 514.
[Full Text] [PDF]


Home page
CirculationHome page
J. van der Linden, G. Lindvall, and U. Sartipy
Aprotinin Decreases Postoperative Bleeding and Number of Transfusions in Patients on Clopidogrel Undergoing Coronary Artery Bypass Graft Surgery: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial
Circulation, August 30, 2005; 112(9_suppl): I-276 - I-280.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. H. Habib, A. Zacharias, T. A. Schwann, C. J. Riordan, S. J. Durham, and A. Shah
Effects of Obesity and Small Body Size on Operative and Long-Term Outcomes of Coronary Artery Bypass Surgery: A Propensity-Matched Analysis
Ann. Thorac. Surg., June 1, 2005; 79(6): 1976 - 1986.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
F. H. Edwards, V. A. Ferraris, D. M. Shahian, E. Peterson, A. P. Furnary, C. K. Haan, and C. R. Bridges
Gender-Specific Practice Guidelines for Coronary Artery Bypass Surgery: Perioperative Management
Ann. Thorac. Surg., June 1, 2005; 79(6): 2189 - 2194.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Milo C. Engoren
Anoar Zacharias
Thomas A. Schwann
Christopher J. Riordan
Samuel J. Durham
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Engoren, M. C.
Right arrow Articles by Durham, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Engoren, M. C.
Right arrow Articles by Durham, S. J.
Related Collections
Right arrow Cardiac - pharmacology


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS